#160596

BDP-13176 Fascin-1 Inhibitor

Cat. #160596

BDP-13176 Fascin-1 Inhibitor

Cat. #: 160596

Sub-type: Inhibitor

Availability: Please enquire for quantities and pricing

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Laura Machesky

Institute: Cancer Research UK, Glasgow: The Beatson Institute

Tool Details
Handling
Target Details
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Tool name: BDP-13176 Fascin-1 Inhibitor
  • Alternate name: FSCN1, Fascin1, Fascin, Fascin actin binding protein
  • Research fields: Cancer
  • Molecular formula: 5-(3,4-dichlorobenzyl)-4-oxo-1-(piperidin-4-yl)-N-(pyridin-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridine-7-carboxamide
  • Chemical name: 5-(3,4-dichlorobenzyl)-4-oxo-1-(piperidin-4-yl)-N-(pyridin-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridine-7-carboxamide
  • Tool sub type: Inhibitor
  • Primary target: Fascin-1
  • Description: Fascin is an actin binding and bundling protein that is not expressed in normal epithelial tissues but overexpressed in a variety of invasive epithelial tumors. It has a critical role in cancer cell metastasis by promoting cell migration and invasion. BDP-13176 is a has potent affinity to Fascin-1, and is capable of inhibiting the binding of Fascin-1 to filamentous actin.
  • Purpose: Inhibitor
  • Molecular weight: 497
  • Additional notes: For detailed technical information, please see the manuscript and supplimentary information on Francis et al., 2019. PMID: 30773430 SPR Kd (ÂľM): 0.08 Ligand efficiency: 0.29 Inhibition of actin bundling IC50 (ÂľM): 0.24 Turbidimetric solubility midpoint (ÂľM): 65 logD7.4: 1.8 Molecular weight (Da): 497 Caco-2 permeability A-B Papp (10-6 cm/s): 0.15 Efflux ratio: 37.8 Microsomal CLint (ÂľL/min/mg protein) Mouse: 11.8 Human: 6.4 CYP450 IC50 (ÂľM) CYP3A4: 7 CYP2D6: 1.6 CYP2C19: 22 CYP2C9: 5.9 hERG IC50 (ÂľM): >25

Handling

  • Purity: 497 g/mol
  • Shipping conditions: Dry Ice

Target Details

  • Primary target: Fascin-1
  • Ic50: 0.24 ± 0.01 ÂľM

References

  • Francis et al. 2019. Bioorg Med Chem Lett. 29(8):1023-1029. PMID: 30773430.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.